Santafe News Online

Delveinsight Business Research LLP

The Adenoid Cystic Carcinoma market report covers emerging drugs, current treatment practices, market share of the individual therapies, current and forecasted market size from 2019 to 2032. It also evaluates the current treatment practice/algorithm, market drivers & barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market. 

Adenoid Cystic Carcinoma: An Overview

Adenoid cystic carcinoma (ACC) is a rare form of adenocarcinoma, a type of cancer that begins in glandular tissues. The underlying cause of ACC is not yet known, but it appears to develop from non-inherited, genetic changes that occur during a person’s lifetime. The exact underlying cause of adenoid cystic carcinoma is unknown. Researchers speculate that genetic and immunologic abnormalities, environmental factors (exposure to ultraviolet rays, certain chemicals, and ionizing radiation), diet, stress, and other factors may play contributing roles in causing specific types of cancer.

According to the Oral Cancer Foundation, Adenoid cystic carcinoma is a form of malignant neoplasm that arises within secretory glands, most commonly the major and minor salivary glands of the head and neck. Other sites of origin include the trachea, lacrimal gland, and skin.

Adenoid Cystic Carcinoma Market Key Facts

• As per the study by Chae et al., the age-adjusted incidence rate of head and neck ACC is 4.5 cases per 100,000 individuals, occurring with a slight female predominance (60% vs. 40% in males).

• According to the Adenoid Cystic Carcinoma Organization, each year, there are approximately 566,000 people diagnosed with cancer in the US, and only about 1224 of them are diagnosed with ACC. Approximately 918 people die from ACC each year.

• A review by Berardinis et al. titled “Adenoid Cystic Carcinoma of Head and Neck” stated that the ACC has a global incidence of 3–4.5 cases per million per year.

Adenoid Cystic Carcinoma Market

The market outlook section of the report helps to build a detailed comprehension of the historic, current, and forecasted Adenoid Cystic Carcinoma market size by analyzing the impact of current and emerging therapies in the market. It also provides a detailed assessment of the market drivers & barriers, unmet needs, and emerging technologies.

The report gives a thorough detail of the Adenoid Cystic Carcinoma market trend for each marketed drug and late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action (MoA), competition with other therapies, brand value, their impact on the market and view of the key opinion leaders.

Adenoid Cystic Carcinoma Epidemiology

The epidemiology section covers insights about the historical and current Adenoid Cystic Carcinoma patient pool and forecasted trends for every seven major countries (7MM)  from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides the diagnosed patient pool and their trends along with assumptions undertaken.  

Adenoid Cystic Carcinoma Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Adenoid Cystic Carcinoma market or expected to get launched in the market during the study period. The analysis covers Adenoid Cystic Carcinoma market uptake by drugs; patient uptake by therapies; and sales of each drug. 

Report’s Drugs Uptake section helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allow the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

The report also covers the Adenoid Cystic Carcinoma Pipeline Development Activities and provides valuable insights about different therapeutic candidates in Phase II, and Phase III stages and the key companies in the market involved in developing targeted therapeutics. It also analyses the recent Development such as collaborations, acquisitions, and mergers, licensing patent details, and other information for emerging therapies.

Get the PDF Sample of the Report:- https://www.delveinsight.com/sample-request/adenoid-cystic-carcinoma-acc-market

Adenoid Cystic Carcinoma Therapeutics Analysis

In the current market scenario, the standard treatment for Adenoid Cystic Carcinoma (ACC) includes Surgery followed by radiation therapy and medical therapy.

The dynamics of the Adenoid Cystic Carcinoma (ACC) market are anticipated to change in the upcoming years owing to the improvement in the diagnosis methodologies, raising awareness of the diseases, incremental healthcare spending across the world, and the expected launch of emerging therapies. Companies across the globe are diligently working toward the development of new treatment therapies for ACC. 

Some of the key companies in the Adenoid Cystic Carcinoma market includes:

• Cellestia Biotech

• Ayala

• CureVac

And others.

Adenoid Cystic Carcinoma Therapies covered in the report includes:

• CB-103

• AL101

And many others.

Get More Detailed Insights into the Emerging Therapies & Key Companies:- https://www.delveinsight.com/sample-request/adenoid-cystic-carcinoma-acc-market

Table of Content

1. Key Insights

2. Executive Summary 

3. Adenoid Cystic Carcinoma Competitive Intelligence Analysis

4. Adenoid Cystic Carcinoma Market Overview at a Glance

5. Adenoid Cystic Carcinoma Disease Background and Overview

6. Adenoid Cystic Carcinoma Patient Journey

7. Adenoid Cystic Carcinoma Epidemiology and Patient Population

8. Adenoid Cystic Carcinoma Treatment Algorithm, Current Treatment, and Medical Practices

9. Adenoid Cystic Carcinoma Unmet Needs

10. Key Endpoints of Adenoid Cystic Carcinoma Treatment

11. Adenoid Cystic Carcinoma Marketed Products

12. Adenoid Cystic Carcinoma Emerging Therapies

13. Adenoid Cystic Carcinoma Seven Major Market Analysis

14. Attribute Analysis

15. Adenoid Cystic Carcinoma Market Outlook (7 major markets)

16. Adenoid Cystic Carcinoma Access and Reimbursement Overview

17. KOL Views on the Adenoid Cystic Carcinoma Market.

18. Adenoid Cystic Carcinoma Market Drivers

19. Adenoid Cystic Carcinoma Market Barriers

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer

*The table of contents is not exhaustive; the final content may vary. 

Request Sample Report here:- https://www.delveinsight.com/sample-request/adenoid-cystic-carcinoma-acc-market

Latest Healthcare Report by DelveInsight

Bevacizumab Biosimilars Insight

DelveInsight’s, “Bevacizumab Biosimilar Insight” report provides comprehensive insights about 40+ companies and 40+ marketed and pipeline drugs in the Bevacizumab Biosimilars Landscape. It covers the marketed and pipeline drug profiles, including clinical and non-clinical stage products.

About DelveInsight

DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end-to-end comprehensive solutions to improve their performance.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/